NASDAQ : BDTX
Black Diamond Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.78 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.27M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 102.27M |
| Enterprise Value | 8.73M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 57.45M |
| Shares Outstanding | 57.45M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 0.67% |
| Owned by Institutions (%) | 53.94% |
| Float | 52.62M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 16.36 |
| PB Ratio | 1.06 |
| P/TBV Ratio | 1.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.28 |
| Quick Ratio | 6.98 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -37.21% |
| Return on Assets (ROA) | -19.11% |
| Return on Invested Capital (ROIC) | -20.90% |
| Return on Capital Employed (ROCE) | -40.81% |
| Weighted Average Cost of Capital (WACC) | 19.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.03M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.33 |
| 52-Week Price Change | -53.40% |
| 50-Day Moving Average | 1.95 |
| 200-Day Moving Average | 2.19 |
| Relative Strength Index (RSI) | 45.38 |
| Average Volume (20 Days) | 915,955 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.00M |
| Short Previous Month | 4.78M |
| Short % of Shares Out | 8.71% |
| Short % of Float | 9.51% |
| Short Ratio (days to cover) | 7.62 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -44.56M |
| Pretax Income | -42.56M |
| Net Income | -42.56M |
| EBITDA | -44.35M |
| EBIT | -44.56M |
| Earnings Per Share (EPS) | -$0.74 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 110.51M |
| Total Debt | 16.97M |
| Net Cash | 93.54M |
| Net Cash Per Share | $1.63 |
| Equity (Book Value) | 96.09M |
| Book Value Per Share | 1.67 |
| Working Capital | 99.55M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -32.84M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 207,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -32.84M |
| FCF Per Share | -$0.57 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.22% |
| Earnings Yield | -41.83% |
| FCF Yield | -32.11% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.00 |
| Price Target Difference | 461.80% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.29 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |